Comparison of gefitinib, erlotinib and afatinib in non‐small cell lung cancer: a meta‐analysis
Gefitinib, erlotinib and afatinib are three widely used epidermal growth factor receptor
tyrosine kinase inhibitors (EGFR TKIs) for treating advanced non‐small cell lung cancer …
tyrosine kinase inhibitors (EGFR TKIs) for treating advanced non‐small cell lung cancer …
Pragmatic issues in biomarker evaluation for targeted therapies in cancer
Predictive biomarkers are becoming increasingly important tools in drug development and
clinical research. The importance of using both guidelines for specimen acquisition and …
clinical research. The importance of using both guidelines for specimen acquisition and …
[HTML][HTML] Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American …
NI Lindeman, PT Cagle, MB Beasley, DA Chitale… - Journal of Thoracic …, 2013 - Elsevier
Objective To establish evidence-based recommendations for the molecular analysis of lung
cancers that are that are required to guide EGFR-and ALK-directed therapies, addressing …
cancers that are that are required to guide EGFR-and ALK-directed therapies, addressing …
Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial
Y Shi, L Zhang, X Liu, C Zhou, S Zhang, D Wang… - The lancet …, 2013 - thelancet.com
Background Icotinib, an oral EGFR tyrosine kinase inhibitor, had shown antitumour activity
and favourable toxicity in early-phase clinical trials. We aimed to investigate whether icotinib …
and favourable toxicity in early-phase clinical trials. We aimed to investigate whether icotinib …
[HTML][HTML] A phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutations
JJ Yang, Q Zhou, HH Yan, XC Zhang, HJ Chen… - British journal of …, 2017 - nature.com
Background: A phase III trial was conducted to compare the safety and efficacy of erlotinib
with that of gefitinib in advanced non-small cell lung cancer harbouring epidermal growth …
with that of gefitinib in advanced non-small cell lung cancer harbouring epidermal growth …
[HTML][HTML] Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG–0803)
YL Wu, C Zhou, Y Cheng, S Lu, GY Chen, C Huang… - Annals of …, 2013 - Elsevier
Background This phase II, open-label study evaluated the efficacy and safety of erlotinib as
second-line therapy in non-small-cell lung cancer (NSCLC) patients with brain metastases …
second-line therapy in non-small-cell lung cancer (NSCLC) patients with brain metastases …
[HTML][HTML] Risk of treatment-related toxicities from EGFR tyrosine kinase inhibitors: a meta-analysis of clinical trials of gefitinib, erlotinib, and afatinib in advanced EGFR …
Introduction Gefitinib, erlotinib, and afatinib are tyrosine kinase inhibitors (TKIs) used for
treatment of advanced EGFR-mutated NSCLC. Estimating differences in toxicity between …
treatment of advanced EGFR-mutated NSCLC. Estimating differences in toxicity between …
[HTML][HTML] Clinical characteristics and prognostic factors in bone metastases from lung cancer
L Zhang, Z Gong - … science monitor: international medical journal of …, 2017 - ncbi.nlm.nih.gov
Results The overall median survival of the 168 patients was 13 months. The 1-year survival
was 54.3% and the 2-year survival was 12.9%. Univariate regression analysis indicated that …
was 54.3% and the 2-year survival was 12.9%. Univariate regression analysis indicated that …
[HTML][HTML] Network meta-analysis of erlotinib, gefitinib, afatinib and icotinib in patients with advanced non-small-cell lung cancer harboring EGFR mutations
W Liang, X Wu, W Fang, Y Zhao, Y Yang, Z Hu, C Xue… - PloS one, 2014 - journals.plos.org
Background Several EGFR-tyrosine kinase inhibitors (EGFR-TKIs) including erlotinib,
gefitinib, afatinib and icotinib are currently available as treatment for patients with advanced …
gefitinib, afatinib and icotinib are currently available as treatment for patients with advanced …
Fighting cancer drug resistance: Opportunities and challenges for mutation-specific EGFR inhibitors
M Juchum, M Günther, SA Laufer - Drug Resistance Updates, 2015 - Elsevier
Multiple mutations in the EGFR gene are a major cause for the failure of Erlotinib and
Gefitinib in the treatment of patients harboring non-small-cell lung cancer (NSCLC) who …
Gefitinib in the treatment of patients harboring non-small-cell lung cancer (NSCLC) who …